Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Tap Tax Cuts and AMED Subsidies, not Price Premium, to Fuel Innovation: JMA Chief
April 7, 2017
- 26 Japan CRO Association Members Enjoy 12.7% Sales Jump in 2016
April 6, 2017
- Kampo Study Group Submits Proposal to LDP Lawmakers, Cites “Concerns About Stable Supply at Current NHI Prices”
April 6, 2017
- 3 Groups Lay Out Guidelines on Inter-Pharmacy Drug Transactions after Harvoni Flub
April 4, 2017
- GHIT Fund to Invest a Total of US$23 Million in 11 Projects
April 3, 2017
- Generic Use Rate at 66.4% in October-December: JGA
March 31, 2017
- Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair
March 28, 2017
- Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging
March 27, 2017
- FPMAJ to Keep Ex-Bureaucrat Kimura as Director General to Secure Lobbying Continuity
March 24, 2017
- JPMA Reprimands Celgene over Side Effect Reporting Violation
March 24, 2017
- Use “Specified Clinical Research” Data for Drug Approval: Regulatory Science Society
March 23, 2017
- Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
- Industry Wants Real-World Data to Serve as Grounds for Drug Pricing: JPMA Head
March 7, 2017
- EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
- 3 Groups to Draw Up Guidelines on Inter-Pharmacy Drug Transactions by March-End
February 27, 2017
- US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
- JMA Calls for Tighter Penalties on Parties Involved in Counterfeits
January 26, 2017
- JPMA Sets Up New Unit as Liaison for APAC
January 20, 2017
- NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
January 20, 2017
- JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics
January 20, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…